Newsletter - July 11, 2019
Expedited FDA Approvals are Now the Norm
Three out of four new drugs approvals by FDA use expedited approval pathways making faster than normal review by FDA the normal process compared to it being used only for exceptional cases about 10 years ago. Also, more than half of the new drugs approved by FDA are for life-threatening diseases and unmet medical needs. Read More
Conflict of Interest and FDA’s Revolving Door
Should FDA officials be restricted in what jobs they can pursue after leaving office? A few days after leaving the FDA, the last Commissioner Scott Gottlieb joined the same venture firm he left to join FDA. Then a few weeks later he joined the Board of Pfizer. In that he joined the long tradition of FDA’s former commissioners pursuing financially lucrative... Read More
Expedited FDA Approvals are Now the Norm
Three out of four new drugs approvals by FDA use expedited approval pathways making faster than normal review by FDA the normal process compared to it being used only for exceptional cases about 10 years ago. Also, more than half of the new drugs approved by FDA are for life-threatening diseases and unmet medical needs. Read More
Conflict of Interest and FDA’s Revolving Door
Should FDA officials be restricted in what jobs they can pursue after leaving office? A few days after leaving the FDA, the last Commissioner Scott Gottlieb joined the same venture firm he left to join FDA. Then a few weeks later he joined the Board of Pfizer. In that he joined the long tradition of FDA’s former commissioners pursuing financially lucrative... Read More
